Login / Signup

Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2- advanced breast cancer: a matching-adjusted indirect comparison.

Hope S RugoVictoria HarmerJoyce O'ShaughnessyKomal JhaveriSara M TolaneyFatima CardosoAditya BardiaVikalp Kumar MaheshwariSandeep TripathiSina HaftchenaryPurnima PathakPeter A Fasching
Published in: Therapeutic advances in medical oncology (2023)
NCT01958021 (MONALEESA-2) and NCT02246621 (MONARCH 3).
Keyphrases
  • clinical evaluation
  • breast cancer risk